Views & Analysis ASCO 2018 - Friday 1st and Saturday 2nd June: Bluebird Bio's... The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance in cancer therapy this year – and latest clinical trial results from t
News Pfizer will have to cut price of AML drug Mylotarg after NIC... NICE blocks access to 65% of patients on cost grounds
News Novartis matches Gilead on price in new CAR-T use Novartis won't offer 'money back' scheme because of delayed effect
News Bluebird bio details plans to file three blockbusters Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
News Jen Norton appointed market access leader at EVERSANA EVERSANA has named Jen Norton as president of its recently formed Market Access & Value division.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
